Pediatrix Medical Group, Inc. Q3 FY2026 earnings call

• Strong Financial Results: Reported adjusted EBITDA of $85 million, exceeding expectations despite rising costs. Consolidated revenue grew by nearly 2% year-over-year.
• Focus on Care Quality: Emphasized that clinical quality is the core agenda for medical directors, citing the nation's largest team of clinicians in women's and children's health as a key competitive advantage.
• Strategic Growth & M&A: Maintained a strong balance sheet with low leverage (0.9x), enabling opportunistic share buybacks ($83M in Q3) and positioning the firm to pursue larger, value-add acquisitions in adjacent women's and children's healthcare areas.
• Telehealth Expansion: Continued expansion of telehealth services as part of internal growth strategies.
• Operational Efficiency: Managed salary expenses effectively, keeping clinical wage inflation consistent at approximately 3% year-over-year, significantly lower than previous mid-to-high single-digit trends.

The transcript does not provide a breakdown of financial performance by specific product segments (e.g., NICU, MFM, OB). The company reports consolidated revenue growth of just under 2%, driven by non-same-unit activity (primarily acquisitions) and same-unit growth of 60 basis points. Same-unit patient service volumes increased by approximately 30 basis points, while same-unit pricing increased by 30 basis points.

• Full-Year Adjusted EBITDA: Narrowed the full-year 2026 outlook range to $290–$300 million from previous broader estimates.
• Q4 Expectations: Implied fourth-quarter adjusted EBITDA of approximately $70–$80 million, providing flexibility against seasonal volume and pricing variability.
• Maintenance/Stability: Guidance reflects a steady state in operations, with no major upward or downward revisions attributed to one-time events, but rather natural seasonality and operational stability.

• No Surprises Act / IDR Process: Management expressed confidence that their predominantly in-network status (<5% out-of-network) mitigates risks from the Independent Dispute Resolution (IDR) process, though they monitor rule changes closely.
• ACA Subsidy Lapse: While currently seeing no negative impact, management acknowledges the potential risk from the lapse of ACA subsidies, noting they are actively tracking population-level insurance valuation changes.
• Hospital Cost Pressures: Increasing costs and pressure on hospital partners could impact negotiation dynamics regarding administrative fees and NICU subsidies, although management believes their efficiency demonstrates clear value.
• Regulatory Uncertainty: Upcoming coding changes for OB hospitals effective in 2027 present uncertainty; management is waiting for final rules before assessing material impact.

Q: Analyst asked for a breakdown of the 30 basis point same-unit pricing increase and its sustainability, specifically regarding payer mix, admin fees, acuity, and RCM tailwinds.

A: CFO detailed that payer mix contributed ~40%, hospital admin fees ~25%, and acuity ~15% to pricing gains. She noted these drivers are sustainable due to favorable payer trends, successful fee negotiations with hospitals, and increasing case complexity. Regarding RCM, she clarified that improved collection activity lapped off, impacting the quarter by over 100 bps negatively, but the business is now in a stable state with ongoing automation efforts.

Q: Analyst questioned the magnitude and risk of the No Surprises Act IDR process, asking if it could become a headwind given alleged abuses by other providers.

A: CEO stated the company is overwhelmingly in-network (<5% out-of-network), so IDR disputes are rare. He expressed confidence that the process fairly balances interests between payers and compliant providers. Since Pediatrics submits claims within the spirit and letter of the rules, they do not expect the review of alleged abuses or rule changes to negatively impact them.

Q: Analyst asked about the strategic rationale behind maintaining a strong balance sheet and low leverage, inquiring if the company would pursue larger acquisitions in adjacent businesses.

A: CEO confirmed that the strong balance sheet allows for larger, value-add acquisitions strictly within the women's and children's healthcare space. He emphasized that share buybacks have been opportunistic and did not deplete cash reserves, ensuring the company remains active in seeking attractive opportunities in their core sector.

Q: Analyst inquired about the impact of upcoming OB hospital coding changes in 2027, asking if unbundling codes might create positive or negative opportunities.

A: CEO declined to predict the impact, noting that rules are not yet finalized and hospital reactions are unknown. He reiterated that this area is not currently material to the business. Management will assess the final rules and market response before determining any strategic shifts, viewing it as an area to watch rather than a current driver.